Summary:
In obese adults with type 2 diabetes mellitus, daily curcumin supplementation (1500 mg) significantly reduced liver fat content, liver stiffness, HbA1c, and markers of inflammation and oxidative stress compared to placebo, though it was associated with mild gastrointestinal discomfort.
| PICO | Description |
|---|---|
| Population | Obese individuals with type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD). |
| Intervention | Oral curcumin supplementation at a daily dose of 1500 mg for 12 months. |
| Comparison | Placebo administered daily over the same 12-month period in a double-blind, randomized, controlled design. |
| Outcome | Curcumin significantly decreased liver fat content, liver stiffness, and HbA1c levels (all p < 0.001). It also improved inflammatory markers (IL-1β, TNF-α) and oxidative stress markers (increased TAC, GPx, SOD; decreased malondialdehyde levels), demonstrating antioxidant and anti-inflammatory effects. Safety assessments showed no significant liver or kidney abnormalities. Mild gastrointestinal discomfort was the most reported non-serious adverse event. |
Source: Metha Yaikwawong, et al. “Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.” Read article here.
